MATIS

The Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS) Study based at @ImperialCollege @ImperialNHS

[MATIS @MATISTrial]

MATIS trial protocol published as a structured summary out now here: https://t.co/VxCuORpp92

@DrAWhittington @VR_Cornelius @CharaniaA

@NikhilVergis @nicholacooper @rachelpips

@andrewinnes007 @melaniesayshi @TYoungstein

[Rigel Pharmaceuticals @RigelPharma]

$RIGL #news - Positive topline data shows #fostamatinib met the primary endpoint of safety in Phase 2 #clinicaltrial in hospitalized patients with #COVID19 - https://t.co/ljRUWks11y

[Graham Cooke @grahamscooke]

Meanwhile on the other side @NEJM, two papers on the role of IL-6 inhibition in those hospitalised with COVID led locally by @nicholacooper @TYoungstein and @agordonICU (https://t.co/nIoHyh8AXO, https://t.co/f2BEATRy1c)

[Imperial Department of Immunology & Inflammation @ImperialImmuno]

Our @nicholacooper is leading a study to evaluate the use of the drugs fostamatinib and ruxolitinib in patients with #COVID19 pneumonia.

Be sure to follow @MATISTrial to stay up to date with the latest findings, and visit our website for more info 👇 https://t.co/cEc8aGYKhx

[MATIS @MATISTrial]

A very warm welcome to Northwick Park which has now joined MATIS! Team effort

@DrAWhittington @NikhilVergis @CatherineHocki1 @nicholacooper @rachelpips @andrewinnes007 @melaniesayshi @TYoungstein

[MATIS @MATISTrial]

100 on the board now for MATIS and well past the halfway point. Well done and keep up the excellent work! @nicholacooper @NikhilVergis @alexxmundell @VR_Cornelius @RachPips @melaniesayshi @CatherineHocki1 @CharaniaA

[MATIS @MATISTrial]

50th patient recruited to the MATIS study today!

Congratulations to the study team! @nicholacooper @NikhilVergis @VR_Cornelius @RachPips @melaniesayshi @CatherineHocki1 @CharaniaA

[Department of Health and Social Care @DHSCgovuk]

Improvements in technology and overlapping clinical trials are among the reasons why COVID-19 vaccines are being developed quickly.

Watch Deputy Chief Medical Officer Professor Jonathan Van-Tam describe in more detail how this saved time 👇

[Jeffrey Strich @JeffreyStrichMD]

Thanks to Dr. Fauci for coming by the NIH ICU to hear more about the patients on our study evaluating fostamatinib for hospitalized patients with COVID-19. https://t.co/IfYDNG8S1T
@TheBethesdaLabs @NIHClinicalCntr @NIHCritCare @nih_nhlbi @YogenKanthi @julieerbalvarez

[National Institute for Health and Care Research @NIHRresearch]

New research has shown the Oxford #COVID19 vaccine, which is administered in two doses, is 70.4% effective overall - or 90% effective if administered as a half dose then a full dose https://t.co/m0u4ToyEO8

[StatsCI @stats_ci]

We are delighted to be part of the MATIS trial team for treatments in COVID-19 pneumonia. It’s a new and welcome experience for efficient trial set up with rapid but careful reviews.

[MATIS @MATISTrial]

Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results https://t.co/NhrSac60gR

🤔

[MATIS @MATISTrial]

First patient recruited today to the MATIS study for COVID-19 pneumonia! @nicholacooper @nvergis

#Letsdobetter

New trial to test anti-inflammatory drugs in patients with COVID-19 pneumonia https://t.co/nyxKveXOzT